UK Markets close in 1 hr 5 mins
  • FTSE 100

    7,490.14
    -28.21 (-0.38%)
     
  • FTSE 250

    20,061.00
    -4.59 (-0.02%)
     
  • AIM

    957.20
    -4.52 (-0.47%)
     
  • GBP/EUR

    1.1799
    -0.0035 (-0.30%)
     
  • GBP/USD

    1.2409
    -0.0083 (-0.6664%)
     
  • BTC-GBP

    23,753.04
    -880.09 (-3.57%)
     
  • CMC Crypto 200

    659.94
    -10.74 (-1.60%)
     
  • S&P 500

    4,020.42
    -68.43 (-1.67%)
     
  • DOW

    32,187.06
    -467.53 (-1.43%)
     
  • CRUDE OIL

    112.62
    +0.22 (+0.20%)
     
  • GOLD FUTURES

    1,810.40
    -8.50 (-0.47%)
     
  • NIKKEI 225

    26,911.20
    +251.45 (+0.94%)
     
  • HANG SENG

    20,644.28
    +41.76 (+0.20%)
     
  • DAX

    14,078.56
    -107.38 (-0.76%)
     
  • CAC 40

    6,383.32
    -46.87 (-0.73%)
     

Publication of Annual Report and Financial Statements for the Year ended 31 December 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Acacia Pharma Group plc
Acacia Pharma Group plc

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

Cambridge, UK and Indianapolis, US – 29 April 2022, 23:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the publication of its Annual Report and Financial Statements for the Year ended 31 December 2021.

The Annual Report is attached below and also available on www.acaciapharma.com in the Investors/Financial Reports and Presentations section.

Contacts

Acacia Pharma Group plc
Mike Bolinder, CEO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com

International Media
Frazer Hall, Mark Swallow, David Dible
MEDiSTRAVA Consulting
+44 20 3928 6900
acaciapharma@medistrava.com

US Investors
LifeSci Advisors
Irina Koffler
+1 917-734-7387
ikoffler@lifesciadvisors.com

Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
chrisvanraemdonck@telenet.be

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting